Some timing and other details may still be subject to change.
Authors may like to pin a passport-size photograph of themselves
on their posters to assist recognition.
__________________________________________________________
Saturday 18th March 2006:
ALTERNATIVES TO ORAL METHADONE OR BUPRENORPHINE FOR AGONIST MAINTENANCE; DEPOT BUPRENORPHINE AND SLOW-RELEASE MORPHINE.
__________________________________________________________
08.30 Welcome and introduction:
Linda Partecke, Colin Brewer.

08.35 Prof. Gabriele Fischer, Vienna.
Slow-release morphine for maintenance.

09.00 Nicolas Clark, Melbourne.
Transfering from high doses of methadone to buprenorphine:
a randomised trial of three different buprenorphine schedules.

09.15 Anish Bhatnagar, San Francisco.
Update on Probuphine.

09.40 U. Havemann-Reinecke, Göttingen.
Influence of psychiatric comorbidity on additional abuse of drugs in maintenance treatment with l- and d/l-methadone.

09.50 Jonathan Moss, Chicago.
Development of the peripheral opiate antagonist methylnaltrexone: potential uses in addiction treatment.

10.05 Discussion

10.15 Coffee break

DEPOT AND IMPLANTED NALTREXONE

10.30 Chair and introduction: Prof. Mats Berglund.

10.35 Prof. Herb Kleber, New York.
Clinical trials of depot naltrexone in opiate abusers.

11.00 (Speaker to be confirmed):
Vivitrol: Development, effectiveness and prospects.

11.25 Arun Starosta, Philadelphia.
From Volpicelli to Vivitrol: Clinical use of long-acting naltrexone in alcoholism: a review.

11.50 Sunil Iyer, Richmond VA.
A ‘bio-relevant’ approach to drug-release:
testing of a biodegradable naltrexone implant.

12.05 Sabine Grüsser-Sinopoli, Berlin.
Naltrexone as anticraving treatment:
a psychophysiological evaluation.

12.20 A.G.Boukje, ’s-Hertogenbosch.
Does naltrexone influence craving in opioid-dependent patients after detoxification?

12.35 T. Kienast, Berlin.
Stable elevations in striatal µ-opioid receptor availability in detoxified alcoholics correlate with alcohol craving:
a [11C]Carfentanil PET study.

12.45 Lunch

13.45 Prof. Gary Hulse, Perth.
Tissue compatibility, biodegradability, blood naltrexone levels, and heroin overdose following treatment of heroin dependent persons with sustained release naltrexone-poly(dl-lactide) implants.

14.10 Linda Partecke, Berlin.
Tissue tolerance and pharmacokinetics of Berlin subcutaneous naltrexone implants.

14.20 Peter Coleman, Richmond VA.
New treatments, new challenges. Persistent heroin use despite naltrexone implantation.

14.35 George O’Neil, Perth.
The problem of intravenous buprenorphine injection with naltrexone implants.

14.50 Björn Axel Johansson, Malmö.
Maintenance treatment with oral naltrexone for opioid dependence: a systematic review and meta-analysis.

15.20 Ross Colquhoun, Sydney.
A comparison of oral and implanted naltrexone in heroin addiction: outcomes at 12 months.

15.40 Tea break

16.00 John Revill, Sheffield.
An audited two-year comparison of 12-month O’Neil naltrexone implantation with supervised methadone maintenance in general practice.

16.15 Nikolaj Kunøe, Oslo.
A matched case-control study of naltrexone implants for relapse prevention in detoxified opioid addicts.

16.30 George O’Neil, Perth.
A review of mortality of patients entering a naltrexone implant treatment programme over a five-year period.

16.45 Michael Ross, Bradford.
Negative correlation between the availability of state-funded (NHS) naltrexone implants and shop theft rates in Bradford, September 2002–March 2005: a natural experiment.

17.00 Colin Brewer, London.
How should psychotherapy and counselling evolve in the implant age?

17.15 Round table to 18.00
Written questions will be invited.

19.30 Reception, dinner.
__________________________________________________________
Sunday 19th March:
RAPID NALTREXONE INDUCTION TECHNIQUES;
anaesthesia, oral sedation or something in-between?
__________________________________________________________

09.00 Chair and introduction: Prof. Gabrielle Fischer.

09.10 Prof. Herb Kleber, New York.
The Columbia study: oral sedation after 24hr buprenorphine stabilisation is equally effective and safer than anaesthesia.

09.35 Cor de Jong, Nijmegen.
General anaesthesia does not improve outcome in opioid antagonist detoxification treatment.

09.50 Catherine de Jong, Amsterdam.
Rapid opioid detoxification under general anaesthesia:
does the benefit of general anaesthesia outweigh the risk?

10.05 John Currie/Peter Cox, Sydney.
Intravenous sedation is a reasonable compromise.

10.20 George O’Neil, Perth.
Out-patient detox services: experience with over 8000 procedures using light i/v sedation.

10.35 Nabil Maksoud, Cairo.
Evolution of techniques over 10 years and 10,000 patients.

10.50 Wayne Moran, Hong Kong.
Rapid opiate detoxification precipitated by subcutaneous naltrexone pellet implantation using ketamine anaesthesia.

10.55 Coffee break

11.15 Discussion

11.35 Sanjay Chugh, New Delhi.
Newer strategies in de-addiction: an Indian perspective.

11.50 Prof. Felix Tretter, Haar.
Differential pharmacological treatments of addiction: methodological implications.

12.10 Ellis Magnée, Oostrum.
Subjective sleep and restless legs before, during and after opiate withdrawal.

12.25 Round table. Where do we go from here?
Written questions will be invited.

13.00 Lunch

DISULFIRAM vs NALTREXONE AND ACAMPROSATE IN ALCOHOLISM

14.00 Chair and introduction: Jonathan Chick, Edinburgh.

14.10 Hannu Alho, Helsinki.
Results of the Helsinki randomised trial of disulfiram,
naltrexone and acamprosate.

14.30 Avinash de Sousa, Mumbai.
Studies of family-supervised disulfiram, naltrexone and acamprosate in an Indian setting.

14.50 Hannah Ehrenreich, Goettingen.
High effectiveness of long-term disulfiram in a structured
out-patient rehabilitation programme.

15.10 Prof. Morris Faiman, Kansas.
An effective disulfiram implant - but is this the way forward?

15.30 Discussion

15.40 Tea break

RAPID BENZODIAZEPINE DETOXIFICATION WITH FLUMAZENIL.

16.00 Chair and introduction: Catherine de Jong.

16.10 John Currie, Sydney.
Experience with 200 in-patients:
safe and effective even from high benzodiazepine doses.

16.40 George O’Neill, Perth.
Rapid benzodiazepine withdrawal as an out-patient procedure. Development and prospects of flumazenil implants.

17.25 Discussion

18.00 Session ends.
__________________________________________________________
Monday 20th March:
WORKSHOP ON RAPID OPIATE/BENZO DETOX AND IMPLANTS 09.00 to 12.00
__________________________________________________________

Dr. Linda Partecke and Dr. Colin Brewer, 19 Feb. 2006